Madrid/Heidelberg, 30 August 2013 - At the Annual General Meeting (AGM) of SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) held on 28 August 2013 shareholders representing about 94 percent of the capital approved all proposals of the Management with an overwhelming majority. Main decisions were related to the discharge of the members of the Supervisory and the Management Board for the past Fiscal Year, the election of new members of the Supervisory Board, the change of the trade name of the Company (new trade name will be: SYGNIS AG), as well as the creation of new authorised capital.
Dr. Wolf-Dieter Starp and Mr. Gonzalo Rodriguez-Fraile Díaz have left the Supervisory Board. Dr. Cristina Garmendia Mendizábal, chairwoman of the Supervisory Board thanked Dr. Starp and Mr. Gonzalo Rodriguez-Fraile Díaz for their work and efforts for SYGNIS Pharma AG. She welcomed Dr. Franz Wilhelm Hopp and Mr. Werner-Friedrich Knuth Schäfer as new members of the Supervisory Board.
At the AGM Pilar de la Huerta, CEO/CFO, confirmed expectations that Qiagen will launch first products with QualiPhi® by autumn 2013.
For further information please contact:
| SYGNIS Pharma AG | |||
| Pilar de la Huerta | |||
| Tel: +34-918063089 | |||
| Email: pdelahuerta@sygnis.es |
About SYGNIS Pharma AG: www.sygnis.de
After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS` new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi® and is currently developing other products in the field of Next Generation Sequencing.
### Disclaimer
Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###